2024 update of the recommendations of the French Society of Rheumatology for the diagnosis and management of patients with rheumatoid arthritis
Recommendations
As issued by the authors
Shared decision between rheumatologist and patient; comprehensive drug and non-drug management for people with rheumatoid arthritis (RA) or at risk of RA development
Diagnosis: importance of clinical arthritis and, in its absence, the risk factors for progression to RA
Treatment: incorporates recent data on the cardiovascular and neoplastic risk profile of JAKi
RA-ILD: clinical screening; high-resolution CT in the presence of pulmonary symptoms
RA-ILD management requires collaboration between rheumatologists and pulmonologists
RA-ILD treatment strategy: control disease activity with MTX or targeted therapies (mainly abatacept or RTX)
Anti-fibrotic treatment should be discussed with a pulmonologist with expertise in RA-ILD
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →